Logo

Ascletis Presents Results of ASC22 (envafolimab) in P-IIb Trial for the Treatment of Chronic Hepatitis B at EASL ILC 2022

Share this
Ascletis Presents Results of ASC22 (envafolimab) in P-IIb Trial for the Treatment of Chronic Hepatitis B at EASL ILC 2022

Ascletis Presents Results of ASC22 (envafolimab) in P-IIb Trial for the Treatment of Chronic Hepatitis B at EASL ILC 2022

Shots:

  • The P-IIb trial evaluates the efficacy & safety of ASC22 (1.0mg/kg, q2w) vs PBO in addition to NAs in 75 patients with CHB for 24wk. and then followed for another 24wks.
  • The results showed that 42.9% of patients with baseline HBsAg ≤100 IU/mL achieved sustained HBsAg loss, ALT flares were reported in 21% of patients while none in the PBO group with more HBsAg reduction, 2 out of 3 patients experienced ALT flares while 1 achieved sustained HBsAg loss starting @4wk. after 2 doses of ASC22
  • Patients experienced a transient seroconversion of anti-HBs @28wk. & stopped NAs treatment 3 days after 24wk. & HBsAg still remained negative until the end of the study, 97.5% were grade 1-2 & no study drug-related SAE was observed

Ref: PRNewswire | Image: Ascletis

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions